Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Molecular Partners AG
Moonlight Bio, Inc
National Institutes of Health Clinical Center (CC)
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
IDEAYA Biosciences
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
AbbVie
M.D. Anderson Cancer Center
Phanes Therapeutics
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Fox Chase Cancer Center
Hutchmed
Hansoh BioMedical R&D Company
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
National Cancer Institute (NCI)
23andMe, Inc.
National Cancer Institute (NCI)
Xencor, Inc.
Tarveda Therapeutics
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)
Stanford University
Virginia Commonwealth University
University of Erlangen-Nürnberg Medical School
University of Southern California
Yale University
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
The University of Texas Health Science Center, Houston
Mannkind Corporation